GlassScriptPhysician profile
Adriana Ackerman
NPI 1740348580
$1,083.26
in general payments reported to CMS, 2019-2025
24 companies · $155 in 2025
The $155 reported for 2025 was less than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $146 · 2022: $216 · 2023: $268 · 2024: $298 · 2025: $155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $721.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $721.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $218.09 | 2021-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $149.09 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $114.48 | 2021-2023 | Ubrelvy |
| Exact Sciences Corporation | $70.93 | 2024-2025 | Cologuard Collection Kit |
| Boston Scientific Corporation | $64.27 | 2022-2024 | Watchman Flx |
| Abbott Laboratories | $62.17 | 2021-2024 | Freestyle Libre 3 |
| Pfizer INC. | $47.73 | 2023-2025 | |
| Corcept Therapeutics | $42.37 | 2023 | Korlym |
| Xeris Pharmaceuticals, INC. | $34.05 | 2023 | Gvoke Hypopen |
| Kowa Pharmaceuticals America, INC. | $27.96 | 2022-2023 | Livalo |
| Lilly USA, LLC | $27.61 | 2021-2022 | |
| Insulet Corporation | $24.86 | 2024 | Omnipod |
| Bayer Healthcare Pharmaceuticals INC. | $20.33 | 2025 | |
| Novartis Pharmaceuticals Corporation | $19.67 | 2024 | |
| Nevro Corp. | $17.81 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baylis Medical Technologies INC. | $17.22 | 2025 | |
| Ibsa Pharma INC. | $17.18 | 2024 | Tirosint, Licart |
| Vbi Vaccine (Delaware) INC. | $17.02 | 2022 | |
| Daiichi Sankyo INC. | $16.65 | 2024 | Injectafer |
| Bausch Health US, LLC | $15.56 | 2025 | Wellbutrin |
| Merck Sharp & Dohme LLC | $15.11 | 2023 | Gardasil 9, Pneumovax 23, Vaxneuvance |
| Biogen, INC. | $15.00 | 2021 | |
| Indivior INC. | $14.90 | 2023 | Sublocade |
| Amgen INC. | $13.20 | 2023 | Repatha, Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adriana Ackerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.